Bausch + Lomb Corporation
NYQ: BLCOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Bausch + Lomb Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get BLCO Z-Score →About Bausch + Lomb Corporation
Healthcare
Medical Instruments & Supplies
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
📊 Fundamental Analysis
Bausch + Lomb Corporation demonstrates a profit margin of -7.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 9.8% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is -5.4%, which indicates that capital utilization is currently under pressure.
At a current price of $16.49, BLCO currently sits at the 71st percentile of its 52-week range (Range: $10.45 - $18.91).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
⚠️
Revenue Growth
Moderate
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$5.86B
Trailing P/E
--
Forward P/E
15.40
Beta (5Y)
0.65
52W High
$18.91
52W Low
$10.45
Avg Volume
411K
Day High
Day Low